FDA inspection backlog woes grow To view this email as a web page,
click here CureVac, Novartis team up in latest pandemic vaccine manufacturing collaboration AHIP, BCBSA team to boost vaccine access for seniors FDA's inspection woes to grow if agency doesn't address COVID-19 backlog: GAO Biden still pushing for his cancer 'breakthrough' dream, but can it work? Large hospital chains post profits in 2020 thanks to higher acuity and liquidity Biopharma roundup—Pfizer supplies vaccines to Brazil AMA: Medicare physician service spending declined $9.4B in first half of 2020 Featured Story | By Eric Sagonowsky CureVac has already attracted two Big Pharma partners for its COVID-19 vaccine work, and now Novartis is getting involved to help with production. The companies have signed an initial manufacturing agreement that’s expected to boost the mRNA biotech’s overall vaccine capacity by 50 million doses in 2021 and 200 million doses in 2022. read more |
| |
|---|
|
Top Stories By Paige Minemyer America's Health Insurance Plans and the Blue Cross Blue Shield Association are joining forces to boost access to vaccinations for seniors and vulnerable populations. read more By Fraiser Kansteiner The FDA needs to address its growing manufacturing inspection backlog or it'll only become more swamped, the U.S. Government Accountability Office has warned. Since last March, the agency has largely paused inspections to play it safe during COVID-19, resulting in a failure to complete more than 1,000 inspections planned for 2020. read more By Ben Adams Like so many in the world, President Joe Biden has been personally hit by a cancer death after the loss of his son Beau in 2015 to a brain tumor. read more By Robert King Larger hospital chains reported profits at the end of the year despite massive patient volume shortfalls created by the COVID-19 pandemic. read more By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale Italy and the European Union have blocked a shipment of AstraZeneca vaccines bound for Australia. The NIH has halted a trial of two COVID-19 antibody treatments. The GAO is examining the FDA's growing inspection backlog, which has been exacerbated by the pandemic. read more By Robert King Medicare physician services spending declined by $9.4 billion in the first half of 2020 due to the COVID-19 pandemic, a new AMA report said. read more |
|
